Monte Rosa Therapeutics, Inc.
NASDAQ: GLUE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Markus Warmuth
- Employees
- 142
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $1.4B
- Website
- https://www.monterosatx.com
Loading GLUE…
Loading profile data…Frequently asked questions about GLUE
What does Monte Rosa Therapeutics, Inc. (GLUE) do?
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a...
Where does GLUE trade?
Monte Rosa Therapeutics, Inc. (GLUE) trades on the NASDAQ Global Select.
What sector is GLUE in?
Monte Rosa Therapeutics, Inc. (GLUE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Monte Rosa Therapeutics, Inc.?
Markus Warmuth is the chief executive officer of Monte Rosa Therapeutics, Inc. (GLUE).
Where is Monte Rosa Therapeutics, Inc. headquartered?
Monte Rosa Therapeutics, Inc. is headquartered in United States.
Does GLUE pay a dividend?
Monte Rosa Therapeutics, Inc. (GLUE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GLUE go public?
Monte Rosa Therapeutics, Inc. (GLUE) completed its initial public offering in 2021.